ABI 201
Alternative Names: ABI-201Latest Information Update: 12 Mar 2025
At a glance
- Originator Avirmax Biopharma
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 28 Feb 2025 Avirmax Biopharma plans to file an IND application for ABI 201 for dry age-related macular degeneration in the fourth quarter of 2025 (Intravitreous) (Avirmax Biopharma pipeline, February 2024)
- 28 Feb 2025 Avirmax Biopharma plans phase-I/II trial for Dry age-related macular degeneration (Intravitreous)
- 07 Feb 2025 Preclinical trials in Dry age-related macular degeneration in USA (Intravitreous) (Avirmax Biopharma pipeline, February 2025)